Zorubicin

Zorubicin

SCHEMBL8231

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(C)=N/NC(=O)c1ccccc1)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 7/20 0.84
PAX8 Q06710 5/20 0.84
BRCA1 P38398 7/20 0.81
STAT6 P42226 5/20 0.81
CYP1A2 P05177 4/20 0.81
P4HB P07237 1/20 0.81
MEN1 O00255 9/20 0.79
THRB P10828 9/20 0.79
KMT2A Q03164 9/20 0.79
RECQL P46063 8/20 0.79
BLM P54132 8/20 0.79
SMN1; SMN2 Q16637 7/20 0.79
HIF1A Q16665 7/20 0.79
MAPT P10636 7/20 0.79
TDP1 Q9NUW8 6/20 0.79
MAPK1 P28482 6/20 0.79
CYP3A4 P08684 5/20 0.79
USP2 O75604 5/20 0.79
TOP2A P11388 5/20 0.79
CHRM1 P11229 4/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zorubicin SCHEMBL13840951 1.00 S100A4 (0.84) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL1651187 1.00 S100A4 (0.84) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL29352324 1.00 S100A4 (0.84) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL8232 1.00 S100A4 (0.84) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL4023 0.99 S100A4 (0.83) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL29617182 0.99 S100A4 (0.83) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL4024 0.99 S100A4 (0.83) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL27835878 0.98 S100A4 (0.81) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL28142133 0.98 MEN1 (0.82) S100A4PAX8BRCA1STAT6CYP1A2
Zorubicin SCHEMBL4759324 0.96 MEN1 (0.79) S100A4PAX8BRCA1STAT6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 47259 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
US-20260137794-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF SYSTIMMUNE INC (US) 2026-05-21 US claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260115305-A1 LINKERS, CONJUGATES AND APPLICATIONS THEREOF GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) 2026-04-30 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
EP-4727589-A1 PROTAMINE-COATED NUCLEIC ACID/THERAPEUTIC AGENT COMPLEXES, AND USES THEREOF The Regents of the University of California (US) 2026-04-22 EP claimed
US-20260091119-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA CELLIS AG (CH) 2026-04-02 US claimed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US claimed
US-5043166-A Antitumor agents; side effect reduction HADASIT MEDICAL RESEARCH, INC. (IL) 1991-08-27 US claimed
CN-1053238-A Morpholinyl derivatives of doxorubicin and process for their preparation FARMTALIA CARLO ERBA S R L (IT) 1991-07-24 CN claimed
EP-0401243-A1 MEDICINAL PREPARATIONS CHARACTERIZED BY A COMBINATION OF CYTOSTATIC AGENTS, HORMONAL THERAPEUTIC AGENTS AND PHOSPHONE DERIVATIVES. HENKEL KGAA (DE) 1990-12-12 EP claimed
EP-0393575-A1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent G.D. Searle & Co. (US) 1990-10-24 EP claimed
CN-1040985-A Anthracycline derivatives and their manufacture method SANRAKU INC (JP) 1990-04-04 CN claimed
CN-1037904-A 3 '-deaminizating-4 '-deoxidation-4 '-the amino anthracene cyclic cpds ERBA FARMITALIA (IT) 1989-12-13 CN claimed
CN-1037539-A The manufacture method of new antitumor antibiotic C-1027 INST OF BIOLOG TECHNOLOGY OF M (CN) 1989-11-29 CN claimed
WO-1989007453-A1 MEDICINAL PREPARATIONS CHARACTERIZED BY A COMBINATION OF CYTOSTATIC AGENTS, HORMONAL THERAPEUTIC AGENTS AND PHOSPHONE DERIVATIVES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1989-08-24 WO claimed
US-4331648-A CARDIOTONIC AGENTS; MOUTH THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1982-05-25 US claimed
US-4320110-A Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats FELICE STEPHEN L DE 1982-03-16 US claimed